Outcome and prognostic factors in ovarian germ cell malignancies

Gynecologic Oncology

Volumn 96, Issue 3, 2005, Pages 784-791

  Lai, Chyong Huey ^a   Chang, Ting Chang ^a   Hsueh, Swei ^b   Wu, Tzu I ^a   Chao, Angel ^a   Chou, Hung Hsueh ^a   Wang, Po Nan ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Germ cell malignancy; High dose chemotherapy; Ovarian neoplasm; Prognosis; Recurrence

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; CANCER RECURRENCE; CANCER SURVIVAL; CHORIOCARCINOMA; DEATH; DYSGERMINOMA; EMBRYONAL CARCINOMA; FEMALE; FOLLOW UP; GERM CELL TUMOR; HISTOLOGY; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TERATOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL RATE; TIME SERIES ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; YOLK SAC TUMOR;

EID: 13844280287     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.11.027     Document Type: Article

References (40)

1. D.M. Gershenson Management of early ovarian cancer: germ cell and sex-cord stromal tumors Gynecol. Oncol. 55 1994 S62 S72
2. S.D. Williams, R. Birch, L.H. Einhorn, L. Irwin, F.A. Greco, and P.J. Loehrer Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide New Engl. J. Med. 316 1987 1435 1440
3. P.E. Schwartz, S.K. Chambers, and J.T. Chambers Ovarian germ cell malignancies: the Yale University experience Gynecol. Oncol. 45 1992 26 31
4. S. Williams, J.A. Blessing, and S.Y. Liao Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group J. Clin. Oncol. 12 1994 701 706
5. F. Peccatori, C. Bonazzi, and S. Chiari Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients Obstet. Gynecol. 86 1995 367 372
6. E.S. Newlands, L. Holden, and K.D. Bagshawe Tumor markers and POMB/ACE chemotherapy in the management of ovarian germ cell tumours (GCTs) Int. J. Biol. Markers 3 1988 185 192
7. S. Williams, J.A. Blessing, P.J. DiSaia, F.J. Major, H.G. Ball, and S.Y. Liao Second-look laparotomy in ovarian germ cell tumors: the Gynecologic Oncology Group experience Gynecol. Oncol. 52 1994 287 291
8. P.L. Mitchell, N. Al-Nasiri, and R. A'Hern Treatment of nondysgerminomatous ovarian germ cell tumors. An analysis of 69 cases Cancer 85 1999 2232 2244
9. M. Brewer, D.M. Gershenson, and C.E. Herzog Outcome and reproductive function after chemotherapy for ovarian dysgerminoma J. Clin. Oncol. 17 1999 2670 2675
10. A. Nawa, N. Obata, and F. Kikkawa Prognostic factors of patients with yolk sac tumors of the ovary Am. J. Obstet. Gynecol. 184 2001 1182 1188
11. D.J.A. Sonneveld, H.J. Hoekstra, and W.T.A. van der Graaf Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era Cancer 91 2001 1304 1315
12. J. Beyer, A. Kramar, and R. Mandanas High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables J. Clin. Oncol. 14 1996 2638 2645
13. M.J. Messing, D.M. Gershenson, M. Morris, T.W. Burke, J.J. Kavanagh, and J.T. Wharton Primary treatment failure in patients with malignant ovarian germ cell neoplasms Int. J. Gynecol. Cancer 2 1992 295 300
14. I.K. El-Lamie, N.A. Shehata, S.K. Abou-Loz, and K.I. El-Lamie Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University Eur. J. Gynecol. Oncol. 21 2000 605 609
15. K. Kanazawa, T. Suzuki, and K. Sakumoto Treatment malignant ovarian germ cell tumors with preservation of fertility. Reproductive performance after persistent remission Am. J. Clin. Oncol. 23 2000 244 248
16. P.J. Loehrer, S.D. John, P. Elson, L.H. Eihorn, and D. Trump Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial J. Clin. Oncol. 13 1995 470 476
17. S. Hinton, P.J. Catalano, and L.H. Eihorn Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors. Final analysis of an intergroup trial Cancer 97 2003 1869 1875
18. F.H. Chang, C.H. Lai, K.K. Chu, T.C. Chang, and I.J. Hung Treatment of malignant germ cell tumors of the ovary J. Formosan Med. Assoc. 93 1994 411 416
19. H.H. Chou, C.H. Lai, P.N. Wan, K.T. Tsai, and S. Hsueh Combination of high dose chemotherapy, autologous bone marrow/peripheral blood stem cell transplantation and thoracoscopic surgery in refractory nongestational choriocarcinoma of a 45 XO/46XY female: a case report Gynecol. Oncol. 64 1997 521 525
20. S. Williams, J.A. Blessing, D.H. Moore, H.D. Homsley, and L. Adcock Cisplatin, etoposide, and bleomycin in advanced and recurrent ovarian germ cell tumors: a trial of the Gynecologic Oncology Group Ann. Int. Med. 111 1989 22 27
21. U.D. Bafna, K. Umadevi, and C. Kurman Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int. J. Gynecol. Cancer 11 2001 300 304
22. S.D. Williams, J.A. Blessing, K.D. Hatch, and S.D. Homsley Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group J. Clin. Oncol. 9 1991 1950 1955
23. M.A. Dimopoulos, M. Papadopoulou, and E. Andreopoulou Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncologic Group study Gynecol. Oncol. 70 1998 70 74
24. G.G. Dark, M. Bower, E.S. Newlands, F. Paradinas, and G.J.S. Rustin Surveillance policy for stage I ovarian germ cell tumors J. Clin. Oncol. 15 1997 620 624
25. A.C. Casey, S. Bhodauria, A. Shapter, R. Nieberg, J.S. Berek, and R. Farias-Eisner Dysgerminoma: the role of conservative surgery Gynecol. Oncol. 63 1996 352 357
26. A. Munkarah, D.M. Gershenson, and C. Levenback Salvage surgery for chemorefractory ovarian germ cell tumors Gynecol. Oncol. 55 1994 217 223
27. A. Jeyakumar, E. Chalas, and A. Hindenburg Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor Gynecol. Oncol. 82 2001 578 580
28. S. Culine, J. Kattan, and C. Lhomme A phase II study of high-dose cisplatin, vinblastine, bleomycin and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary Gynecol. Oncol. 54 1994 47 53
29. R. De Wit, G. Stoler, and S.B. Kaye Importance of bleomycin in combination chemotherapy for good-prognosis testicular nomseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group J. Clin. Oncol. 15 1997 1837 1843
30. C.R. Nichols, P.J. Catalano, E.D. Crawford, N.J. Vogelzang, L.H. Eihorn, and P.J. Loehrer Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study J. Clin. Oncol. 16 1998 1287 1293
31. B. Cushing, R. Giller, and J.W. Cullen Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a Pediatric Oncology Group 9049 and Children's Cancer Group 8882 J. Clin. Oncol. 22 2004 2691 2700
32. H.J. Schmoll, C. Kollmannsberger, and B. Metzner Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Study Group J. Clin. Oncol. 21 2003 4083 4091
33. C. Bokemeyer, C. Kollmannsberger, and C. Meisner First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and patched-pair analysis J. Clin. Oncol. 17 1999 3450 3456
34. O. Rick, O.R.C. Bokemeyer, and J. Beyer Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stim-cell rescue in patients with repalsed or refractory germ cell cancer J. Clin. Oncol. 19 2001 81 88
35. G. Rosti, U. de Giorgi, and R. Salvioni Salvage high-dose chemotherapy in patients with germ cell tumors. An Italian experience with 84 patients Cancer 95 2002 309 315
36. A.B. Sandler, A. Cristou, and S. Fox A phase II trial of paclitaxel in refractory germ cell tumors Cancer 82 1998 1381 1386
37. C. Bokemeyer, A. Gerl, and P. Schoffski Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer J. Clin. Oncol. 17 1999 512 516
38. T. Miki, Y. Mizutani, and N. Nonomura Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors Cancer 95 2002 1879 1885
39. C. Kollmannsgerger, J. Beyer, and R. Liersch Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group J. Clin. Oncol. 22 2004 108 114
40. D.J.A. Sonneveld, D.T. Sleijfer, H.S. Koops, M.E. Keemers-Gels, W.M. Molenaar, and H.J. Hoekstra Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors Cancer 82 1998 1343 1351